LCTX PE Ratio & Valuation, Is LCTX Overvalued

Historical Valuation

Lineage Cell Therapeutics Inc (LCTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 30.61 is considered Undervalued compared with the five-year average of -9.59. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 265.89 to 266.87 according to relative valuation method. Compared to the current price of 1.81 USD , Lineage Cell Therapeutics Inc By Undervalued By 99.32%.

Relative Value

Fair Zone

265.89-266.87

Current Price：1.81

99.32%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lineage Cell Therapeutics Inc (LCTX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lineage Cell Therapeutics Inc (LCTX) has a current Price-to-Book (P/B) ratio of 17.14. Compared to its 3-year average P/B ratio of 4.35, the current P/B ratio is approximately 294.19% higher. Relative to its 5-year average P/B ratio of 3.82, the current P/B ratio is about 348.33% higher. Lineage Cell Therapeutics Inc (LCTX) has a Forward Free Cash Flow (FCF) yield of approximately -5.25%. Compared to its 3-year average FCF yield of -13.22%, the current FCF yield is approximately -60.28% lower. Relative to its 5-year average FCF yield of -8.80%, the current FCF yield is about -40.33% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LCTX competitors is 19521.71, providing a benchmark for relative valuation. Lineage Cell Therapeutics Inc Corp (LCTX.A) exhibits a P/S ratio of 30.61, which is -99.84% above the industry average. Given its robust revenue growth of 130.40%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LCTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LCTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LCTX currently overvalued or undervalued?

Lineage Cell Therapeutics Inc (LCTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 30.61 is considered Undervalued compared with the five-year average of -9.59. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 265.89 to 266.87 according to relative valuation method. Compared to the current price of 1.81 USD, Lineage Cell Therapeutics Inc is Undervalued By 99.32%.

What is Lineage Cell Therapeutics Inc (LCTX) fair value?

LCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 265.89 to 266.87 according to relative valuation method.

How does LCTX's valuation metrics compare to the industry average?

The average P/S ratio for LCTX's competitors is 19521.71, providing a benchmark for relative valuation. Lineage Cell Therapeutics Inc Corp (LCTX) exhibits a P/S ratio of 30.61, which is -99.84% above the industry average. Given its robust revenue growth of 130.40%, this premium appears sustainable.

What is the current P/B ratio for Lineage Cell Therapeutics Inc (LCTX) as of Mar 11 2026?

As of Mar 11 2026, Lineage Cell Therapeutics Inc (LCTX) has a P/B ratio of 17.14. This indicates that the market values LCTX at 17.14 times its book value.

What is the current FCF Yield for Lineage Cell Therapeutics Inc (LCTX) as of Mar 11 2026?

As of Mar 11 2026, Lineage Cell Therapeutics Inc (LCTX) has a FCF Yield of -5.25%. This means that for every dollar of Lineage Cell Therapeutics Inc's market capitalization, the company generates -5.25 cents in free cash flow.

What is the current Forward P/E ratio for Lineage Cell Therapeutics Inc (LCTX) as of Mar 11 2026?

As of Mar 11 2026, Lineage Cell Therapeutics Inc (LCTX) has a Forward P/E ratio of -16.22. This means the market is willing to pay $-16.22 for every dollar of Lineage Cell Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lineage Cell Therapeutics Inc (LCTX) as of Mar 11 2026?

As of Mar 11 2026, Lineage Cell Therapeutics Inc (LCTX) has a Forward P/S ratio of 30.61. This means the market is valuing LCTX at $30.61 for every dollar of expected revenue over the next 12 months.

LCTX Valuation